In Parkinson’s disease (PD), a protein called alpha-synuclein (α-syn) and its mutants forms misfolds and aggregates to form toxic fibrils that accumulate into Lewy bodies and Lewy neurites within neurons. These aggregates are a hallmark of PD, leading to selective neuronal death and synaptic dysfunction.
Monomeric α-synuclein is intrinsically disordered in solution. During aggregation, it transitions from an α-helical to a β-sheet–rich structure — forming oligomers, protofibrils, and finally mature fibrils. This structural conversion is central to amyloid formation and toxicity.
🧩 A promising therapeutic strategy focuses on preventing or dissolving these fibrillar structures. One innovative approach involves PROTACs (Proteolysis Targeting Chimeras) - bifunctional molecules that recruit an E3 ubiquitin ligase to selectively tag the target protein for degradation by the proteasome.
A recent study by Shen et al. (2025) (https://www.sciencedirect.com/science/article/pii/S0021925825022999) demonstrated this concept beautifully. They designed a PROTAC that links a benzothiazone moiety (binding to the hydrophobic sites on the fibrils) to an arginine moiety (recruiting the E3 ligase UBR1). This molecule –Arg-PEG1-Tα-syn - significantly reduced α-syn aggregates and associated toxicity in both mammalian cells and C. elegans models.
These findings highlight the potential of amino acid–based PROTACs targeting α-syn for degradation - opening a new avenue for treating Parkinson’s disease and other synucleinopathies.
🔬 The road ahead is long, but the idea of degrading rather than inhibiting misfolded proteins could redefine how we approach neurodegenerative diseases.Write your text here...
